Jaguar Health today announced that it has signed a memorandum of understanding with the lead sponsor of the planned Dragon SPAC, which is pursuing a listing on AIM Italia. Napo EU, the anticipated subsidiary of the company in Italy, will be the named target of the Dragon SPAC and has granted the Dragon SPAC exclusivity to list on AIM Italia and negotiate and finalize the documentation for the contemplated merger transaction.
The Dragon SPAC is a newly formed initiative expected to be incorporated in Italy, with lead sponsorship by Josh Mailman, a New York City-based impact investor.
Jaguar Health is engaged in the development of a variety of therapies, including treatments for chronic COVID patients. Read more.
